Progress Toward Onchocerciasis Elimination in Brazil

• Published in: The American journal of tropical medicine and hygiene Vol. 111; no. 3_Suppl; p. 137
• Main Authors: Pereira de Araujo, João Luiz, Ríos, Dalila, Grillet, Maria Eugenia, da Cruz, Alda Maria, Rakers, Lindsay, Richards, Frank, Francis Schuertz, Heriberto, Durães, Sandra Maria Barbosa
• Format: Journal Article
• Language: English
• Published: United States 03-09-2024
• Subjects: Brazil - epidemiology; Disease Eradication - methods; Filaricides - therapeutic use; Humans; Ivermectin - therapeutic use; Mass Drug Administration; Onchocerciasis - drug therapy; Onchocerciasis - epidemiology; Onchocerciasis - prevention & control; Brazil
• ISSN: 1476-1645
• DOI: 10.4269/ajtmh.23-0749

The single onchocerciasis-endemic focus in the remote Amazon rainforest is shared by Brazil and Venezuela and affects primarily the indigenous Yanomami people. Regional elimination of onchocerciasis is challenged by the magnitude and inaccessibility of this area. In Brazil, 272 onchocerciasis-endemic communities are operationally organized through 21 health centers ("polos bases"). Mass drug administration of ivermectin began in 1995, with 36 effective biannual rounds (≥85% coverage of the eligible population) through 2022. The national on chocerciasis program maintains community-level monitoring to prioritize treatment activities and epidemiological surveys. The Onchocerciasis Elimination Program for the Americas and the WHO onchocerciasis elimination guidelines have helped Brazil move toward its goal of stopping ivermectin treatment by 2025 and verifying transmission elimination by 2030. Additional challenges to the Brazilian onchocerciasis program include cross-border movements and insecurity due to illegal mining and inter-community conflicts. The new government in Brazil offers hope given its commitment to the equity of indigenous people and preservation of the Amazon environment.